Related Experiment Videos
Acral erythema: a clinical review
1Department of Dermatology, University of Texas Medical School, Houston 77030.
Cutis
|March 1, 1993
Summary
Acral erythema is a chemotherapy side effect seen in cancer patients. This case highlights its occurrence in acute myelogenous leukemia following specific chemotherapy agents.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Acral erythema is a known cutaneous reaction to chemotherapy.
- It is observed in patients with both hematologic malignancies and solid tumors.
Observation:
- A case of acral erythema in a woman with acute myelogenous leukemia is presented.
- The patient initially had Sweet's syndrome lesions during blast crisis.
Findings:
- Acral erythema developed after treatment with cytosine arabinoside and idarubicin.
- Cytosine arabinoside and idarubicin are common chemotherapy agents used for acute myelogenous leukemia.
Implications:
- Understanding chemotherapy-induced skin reactions is crucial for patient management.
- Further research into the pathogenesis and treatment of acral erythema is warranted.